Detection of recurrence after radiation therapy using C-11 methionine PET

Detection of recurrence after radiation therapy using C-11 methionine PET - Detection of recurrence after radiation therapy using C-11 methionine PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016128

Enrollment

Registered

2015-01-08

Start date

2015-01-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary or secoundary brain tumor, Tumor of the neighboring organ

Interventions

PET

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: "(1) The patients with suspected recurrence of tumor more than a half year after radiation theray (2) The patients that enough diagnosis information is not obtained by the common imaging (CT, MRI) (3) The patients or the patients that a written agreement is obtained about participation of this study by legal representative "

Exclusion criteria

Exclusion criteria: "(1) The patients with a history of hypersensitivity for C-11 methionine or F-18 FDG. (2) A pregnant woman, nursing mother and the women who may be pregnant (3) The patients who participate in other trials (4) The patients who receive C-11 methioine PET within 90 days (5) The patients whom it is assumed overall status to have difficulty in application of the surgical treatment (6) The patients whom brain metastasis appeared outside of radiation fields (7) The patients that a primary tumor and other metastases caused exacerbation for a metastatic brain tumor remarkably (8) The patients whom it was multiple, and metastasis appeared for a primary cerebral tumor any place other than fields (9) When it is multiple, and a lesion with suspected recurrence of tumor develops independently than three places outside in fields or fields (10) In addition, the patients whom a study person in charge judged to be inadequate as subjects "

Design outcomes

Primary

Measure	Time frame
Superiority of the sensitivity of C-11 methionine PETover that of F-18 FDG	—

Secondary

Measure	Time frame
"Efficacy: (1) Agreement between the histopathology result and C-11 methionine PET result and F-18 FDG (2) Positive-predictive value (PPV) of C-11 methionine PET (3) The number of cases that treatment strategy was changed from medical treatment to surgical or radiotherapy. (4) PET imaging agreement rate between readers of third party interpretation Committee Safety: Adverse event "	—

Countries

Japan

Contacts

Public ContactCoordination Secretariat

Hokkaido University Graduate School of Medicine Depertment of Nuclear Medicine

tshiga@med.hokudai.ac.jp011-706-5152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026